Selloff or Market Correction? Either Way, Here's What to Do NextSee Overvalued Stocks

Guggenheim sets stock target on Neogen, starts at Buy on trajectory

EditorNatashya Angelica
Published 12/19/2024, 08:41 AM
NEOG
-

On Thursday, Guggenheim initiated coverage on shares of Neogen (NASDAQ:NEOG) Corporation (NASDAQ: NEOG), assigning the stock a Buy rating with a price target set at $15.00. Currently trading at $11.64, near its 52-week low of $11.46, Neogen is recognized as a leader in the food safety testing sector, holding a 20% share of the global market.

Despite facing difficulties integrating the recently acquired 3M Food Safety business, which impacted the company's growth and margins, Guggenheim believes Neogen is on the path to recovery.

The company's journey has been marked by integration challenges following the acquisition, which have continued to influence its financial performance. With annual revenue of $912.2 million and a strong liquidity position reflected in a current ratio of 4.41, the analyst from Guggenheim expressed optimism about Neogen's future, citing the market potential, effective management, and the company's long-term financial prospects as reasons for the positive outlook.

Neogen's market positioning as a top pure-play food safety testing company is significant in the context of the global market. The company's 20% market share underscores its influence and the scale of its operations within the industry.

Guggenheim's initiation of coverage with a Buy rating reflects confidence in Neogen's ability to address its current challenges. The $15 price target suggests a positive trajectory for the company's stock value, as it works towards resolving its integration issues and capitalizing on its market position.

The analyst's comments highlight the attractiveness of Neogen's management and financial profile in the long term. This assessment is crucial for potential investors considering Neogen's stock as Guggenheim signals a turning point for the company.

According to InvestingPro analysis, Neogen appears slightly undervalued at current levels, with multiple ProTips indicating both challenges and opportunities ahead. Discover more detailed insights and a comprehensive Pro Research Report covering Neogen's financial health and growth prospects on InvestingPro.

In other recent news, Neogen Corporation experienced a challenging start to the fiscal year 2025, with Q1 revenues declining to $217 million. The Food Safety segment generated $159 million, marking a 4% decrease, while the Animal Safety revenues stood at $58 million, down by 8%.

Despite the 1% core revenue decline, the company remains optimistic, maintaining its full-year guidance for 2025. The company's adjusted EBITDA was reported at $44 million, with a margin of 20.1%.

Neogen anticipates improved margins in the coming months, driven by higher revenue and operational efficiencies. The firm also foresees a stronger performance in the second half of the fiscal year, with a slight improvement already observed in early Q2 compared to Q1.

In other recent developments, Neogen shareholders rejected the proposed executive compensation package but re-elected all nominated directors in a recent meeting. The company's independent registered public accounting firm, BDO USA, P.C., was ratified for the fiscal year ending May 31, 2025.

Leadership changes are underway at Neogen, including the planned retirement of COO Doug Jones in early 2025 and the search for a new Chief Commercial Officer.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.